Jazz Pharma invests in first manufacturing facility in Ireland

10 February 2014

Specialty drugmaker Jazz Pharmaceuticals (Nasdaq: JAZZ) has commenced construction of a manufacturing and development facility to be located on a 17-acre site in Monksland, County Roscommon, around 75 miles east of the company's Dublin headquarters. This is the first manufacturing facility to be built by the company.

Jazz Pharma expects to invest about $60–$68 million in construction, development and personnel costs to build and open the 55,000 ft2 (5,100 m2) facility. The investment is being supported by the Irish Government's Department of Jobs, Enterprise and Innovation through IDA Ireland.

"Today marks a milestone for Jazz Pharmaceuticals as we break ground in Ireland and begin, for the first time, construction on a manufacturing and development facility," said Bruce Cozadd, chairman and chief executive of Jazz Pharma. "This investment not only strengthens our international manufacturing capabilities, but importantly represents our commitment to expanding our presence in Ireland."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK